Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome

Leukemia

Volumn 12, Issue 5, 1998, Pages 675-681

  Gruhn, B ^a,b   Hongeng, S ^a   Yi, H ^a   Hancock, M L ^a   Rubnitz, J E ^a   Neale, G A M ^a   Kitchingman, G R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Acute lymphoblastic leukemia; Minimal residual disease; Polymerase chain reaction

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISONE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BONE MARROW CELL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOGLOBULIN GENE; LEUKEMIA CELL; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE;

EID: 0031921578     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400985     Document Type: Article

References (14)

1. Pui C-H. Childhood leukemias. New Engl J Mod 1995; 332: 1618-1630.
2. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet 1996; 347: 1783-1788.
3. Hagenbeck A. Minimal residual disease in leukemia: state of the art 1991. Leukemia 1992; 6 (Suppl. 2): 12-16.
4. Felix CA, Poplack DG, Reaman GH, Steinberg SM, Cole DE, Taylor BJ, Begley CG, Kirsch IR. Characterization of immunoglobulin and T cell receptor gene patterns in B cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990; 8: 431-442.
5. Blackwell TK, Alt FW. Molecular characterization of the lymphoid V(D)J recombination activity. J Biol Chem 1989; 264: 10327-10330.
6. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302: 575-581.
7. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morley AA. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
8. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 1879-1888.
9. Roberts WM, Estrov Z, Ouspenskaia MV, Johnston DA, McClain KL, Zipf TF. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New Engl J Med 1997; 336: 317-323.
10. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martial P. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993; 82: 1618-1625.
11. Evans WE, Rodman J, Relling MV, Crom WR, Rivera GK, Crist WM, Pui C-H. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991; 28 (Suppl. 4): 15-21.
12. Pui C-H, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, Synold T, Relling MV, Ribeiro RC, Crist WM, Evans WE. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. New Engl J Med 1997; 336: 1781-1787.
13. Pui C-H, Rivera GK, Evans WE, Sandlund JT, Hancock ML, Relling MV, Boyett J, Ribeiro RC, Furman WL, Mahmoud HH, Hurwitz C, Crist WM. Current treatment and results of St Jude studies for childhood acute lymphoblastic leukemia. Haematol Blood Transfus 1994; 36: 307-313.
14. Wigler M, Sweet R, Sim GK, Wold B, Pellicer A, Lacy E, Maniatis T, Silverstein S, Axel R. Transformation of mammalian cells with genes from procaryotes and eucaryotes. Cell 1979; 16: 777-785.